Physician profile
Marc Peiper
NPI 1780673509
$5,264.16
in general payments reported to CMS, 2019-2025
46 companies · $45.98 in 2025
The $45.98 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,005 · 2022: $1,662 · 2023: $1,468 · 2024: $1,084 · 2025: $45.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,933 · Long Term Medical Supply Or Device Loan: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,932.78 |
| Long Term Medical Supply Or Device Loan | $665.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,225.67 | 2021-2025 | |
| Janssen Biotech, INC. | $418.02 | 2021-2023 | Rybrevant |
| Genzyme Corporation | $250.67 | 2021-2023 | |
| Pfizer INC. | $241.86 | 2021-2022 | |
| Incyte Corporation | $219.82 | 2021-2023 | Jakafi, Pemazyre, Monjuvi |
| Glaxosmithkline, LLC. | $206.54 | 2021-2024 | Zejula, Jemperli, Shingrix |
| Daiichi Sankyo INC. | $202.36 | 2021-2024 | Enhertu |
| Merck Sharp & Dohme LLC | $191.07 | 2021-2023 | Keytruda, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $190.02 | 2021-2023 | Imbruvica |
| Celgene Corporation | $167.03 | 2021-2023 | Opdualag, Reblozyl |
| Neurocrine Biosciences, INC. | $122.01 | 2024 | Ingrezza |
| Eisai INC. | $119.00 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $110.97 | 2021-2023 | Xarelto |
| Seagen INC. | $104.91 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Regeneron Healthcare Solutions, INC. | $94.82 | 2023-2024 | Libtayo |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Peiper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.